Biogen (BIIB) Announces Amended Agreement with Neurimmune Holding AG on Investigational Alzheimer's Disease Treatment Aducanumab
Tweet Send to a Friend
Biogen (NASDAQ: BIIB) announced today that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
